Evidence map›Paper›PMID 40506236›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

Preirradiation of Spheroids with

Hima Tallam, Rajiv Nair, Aira Sarkar, Sumudu Katugampola, Stavroula Sofou, Roger W Howell

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hima TallamDepartment of Radiology and Center for Cell Signaling, New Jersey Medical School, Rutgers University, Newark, New Jersey.
Rajiv NairDepartment of Chemical and Biomolecular Engineering, Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland; and.
Aira SarkarDepartment of Chemical and Biomolecular Engineering, Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland; and.
Sumudu KatugampolaDepartment of Radiology and Center for Cell Signaling, New Jersey Medical School, Rutgers University, Newark, New Jersey.
Stavroula SofouDepartment of Chemical and Biomolecular Engineering, Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland; and rhowell@rutgers.edu ssofou1@jhu.edu.
Roger W HowellDepartment of Radiology and Center for Cell Signaling, New Jersey Medical School, Rutgers University, Newark, New Jersey; rhowell@rutgers.edu ssofou1@jhu.edu.

Funding

MIRDcell Version 3R01CA245139 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Roger W. Howell · 2020 to 2026
$1.8M
NCI NIH HHS R01 CA245139
6 · The paper itself

Abstract

This investigation examined the factors involved in predicting the responses of micrometastases to targeted

Indexed as

ActiniumSpheroids, CellularTrastuzumabCell Line, TumorHumansLiposomesRadiopharmaceuticalsActiniumLiposomesRadiopharmaceuticalsTrastuzumab225Ac-liposome225Ac-trastuzumabdosimetrymicrometastasisradiopharmaceutical therapy

Identifiers

PMID40506236
PMCPMC12320574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.